Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFα/NF-B signaling axis

Leukemia

Volumn 24, Issue 8, 2010, Pages 1476-1486

  Zak, Z ^a   Gelebart, P ^a   Lai, R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cell death; fenofibrate; mantle cell lymphoma

Indexed keywords

CASPASE 3; CYCLIN D1; FENOFIBRATE; GW 6471; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PIRINIXIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN DNA BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 77955717702     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.117     Document Type: Article

References (46)

1. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
2. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-424.
3. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-895.
4. Green S, Wahli W. Peroxisome proliferator-activated receptors: finding the orphan a home. Mol Cell Endocrinol 1994; 100: 149-153.
5. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497-505.
6. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790-793.
7. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169: 453-459. (Pubitemid 32536978)
8. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cyto-kine production in aging. J Biol Chem 1998; 273: 32833-32841.
9. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999; 274: 32048-32054.
10. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 1998; 36: 345-349.
11. Reddy JK, Azarnoff DL, Hignite CE. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 1980; 283: 397-398.
12. Gonzalez FJ. The peroxisome proliferator-activated receptor alpha (PPARalpha): role in hepatocarcinogenesis. Mol Cell Endocrinol 2002; 193: 71-79.
13. Childs M, Girardot G. [Evaluation of acquired data on long-term risk of hypolipidemic treatments]. Arch Mal Coeur Vaiss 1992; 85(Spec No. 2): 129-133.
14. Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C et al. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res 2004; 64: 3849-3854.
15. Laurora S, Pizzimenti S, Briatore F, Fraioli A, Maggio M, Reffo P et al. Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells. J Pharmacol Exp Ther 2003; 305: 932-942.
16. Scatena R, Nocca G, Sole PD, Rumi C, Puggioni P, Remiddi F et al. Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ 1999; 6: 781-787. (Pubitemid 29425389)
17. Liu H, Zang C, Fenner MH, Liu D, Possinger K, Koeffler HP et al. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood 2006; 107: 3683-3692.
18. Shigeto T, Yokoyama Y, Xin B, Mizunuma H. Peroxisome proliferator- activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer. Oncol Rep 2007; 18: 833-840.
19. Muzio G, Maggiora M, Oraldi M, Trombetta A, Canuto RA. PPARalpha and PP2A are involved in the proapoptotic effect of conjugated linoleic acid on human hepatoma cell line SK-HEP-1. Int J Cancer 2007; 121: 2395-2401.
20. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, Fannon M et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 2008; 105: 985-990.
21. Swerdlow S, Berger F, Isaacson P, Muller-Hermelink H. Mantle cell lymphoma. In: Harris NL, Jaffe ES, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001.
22. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750-762.
23. Smith MR. Mantle cell lymphoma: advances in biology and therapy. Curr Opin Hematol 2008; 15: 415-421.
24. Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63: 8226-8232.
25. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88-95.
26. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apop-tosis in mantle cell lymphoma. Biochem Pharmacol 2005; 70: 700-713.
27. Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006; 107: 4540-4548.
28. Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM et al. Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels. Mol Cancer Ther 2008; 7: 749-758.
29. Rizzatti EG, Falcao RP, Panepucci RA, Proto-Siqueira R, Anselmo-Lima WT, Okamoto OK et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 2005; 130: 516-526.
30. Rizzatti EG, Mora-Jensen H, Weniger MA, Gibellini F, Lee E, Daibata M et al. Noxa mediates bortezomib induced apoptosis inboth sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leuk Lymphoma 2008; 49: 798-808.
31. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009; 114: 1469-1476.
32. Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL et al. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 2003; 127: 424-431.
33. Gelebart P, Zak Z, Anand M, Dien-Bard J, Amin HM, Lai R. Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism. Leukemia 2009; 23: 1836-1846.
34. Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 2002; 415: 813-817.
35. Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008; 22: 2097-2105.
36. Gizard F, Nomiyama T, Zhao Y, Findeisen HM, Heywood EB, Jones KL et al. The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation. Circ Res 2008; 103: 1155-1163.
37. Zhao X, Li LY. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol 2008; 28: 598-606.
38. Saidi SA, Holland CM, Charnock-Jones DS, Smith SK. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer 2006; 5: 13.
39. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion mole-cule-1 expression in human endothelial cells. Circulation 1999; 99: 3125-3131.
40. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 323-330.
41. Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004; 43: 1481-1488.
42. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
43. Guay DR. Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother 1999; 33: 1083-1103.
44. Zambon A, Cusi K. The role of fenofibrate in clinical practice. Diab Vasc Dis Res 2007; 4 (Suppl 3): S15-S20.
45. Steinhoff M, Beyer M, Roewert-Huber J, Lukowsky A, Assaf C, Sterry W. Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. J Am Acad Dermatol 2008; 58 (5 Suppl 1): S88-S91.
46. Krempf M, Rohmer V, Farnier M, Issa-Sayegh M, Corda C, Sirugue I et al. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200-400mg daily with placebo in patients with hyper-cholesterolemia. Diabetes Metab 2000; 26: 184-191.